Your session is about to expire
← Back to Search
brentuximab vedotin for Hodgkin's Lymphoma
Study Summary
This trial will study brentuximab vedotin for treating Hodgkin lymphoma and peripheral T-cell lymphoma in patients who are unable to have standard chemotherapy.
- Hodgkin's Lymphoma
- Peripheral T-Cell Lymphoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 452 Patients • NCT01777152Trial Design
Who is running the clinical trial?
Media Library
- You cannot be using any other experimental drugs at the same time.You must have completed chemotherapy, radiotherapy, biologics, and/or other treatments with immunotherapy at least 4 weeks before starting the study drug.You do not have a kidney disease that needs dialysis.You have had another type of cancer within 1 year before starting the study drug.- You have received immune-oncology therapy before.
- You have a known or suspected autoimmune disease.
- You have had an allogeneic stem cell transplant in the past.
- You have had a cerebral vascular event (stroke) within 6 months before starting the study.
- You have interstitial lung disease that is causing symptoms or may affect the ability to monitor for drug side effects.
- You have a history of pancreatitis.
- Group 1: Part E: Brentuximab Vedotin in HL Patients
- Group 2: Part D: Brentuximab Vedotin + Nivolumab in HL Patients
- Group 3: Part C: Brentuximab Vedotin + Bendamustine in HL Patients
- Group 4: Part F: Brentuximab Vedotin in PTCL Patients
- Group 5: Part A: Brentuximab Vedotin in HL Patients
- Group 6: Part B: Brentuximab Vedotin + Dacarbazine in HL Patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions are typically addressed through the use of brentuximab vedotin?
"Brentuximab vedotin has proven to be a successful treatment for individuals suffering from unresectable melanoma, squamous cell carcinoma, and pheochromocytomas."
Are there vacancies in this medical experiment that individuals can fill?
"Affirmative. The clinical trial hosted on the website clinicaltrials.gov is actively recruiting patients, with 180 participants needing to be enrolled at 39 different sites. This research project was first announced on October 31st 2012 and received its last update November 11th 2022."
What empirical evidence exists for the efficacy of brentuximab vedotin?
"In 2002, brentuximab vedotin was first evaluated at Canberra Hospital. Nowadays, there are 506 complete clinical trials and 860 active ones taking place around the world; a noticable concentration of these studies being conducted in Montreal, Quebec."
How many locations within this city are participating in the clinical trial?
"Currently, 39 clinical trial sites are participating in the recruitment process. These medical centres are situated in Montreal, Arlington and Fairfax as well as 36 additional locations across North America. To reduce travel-related costs for participants, it is advised to select a clinic within close proximity of your home."
Is brentuximab vedotin permissible under the guidelines of the Food and Drug Administration?
"Brentuximab vedotin has been evaluated for safety in a Phase 2 trial, thereby earning it an estimated score of 2. However, there is currently no data available to support its efficacy."
What is the current enrollment quota for this clinical trial?
"This clinical trial necessitates 180 patients that satisfy the eligibility requirements. Potential participants can visit Royal Victoria Hospital, McGill University Health Centre in Montreal, Quebec and Arlington Cancer Center in Arlington, Texas to be considered for this study."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger